Ki-67、p53、雌激素受体、倍体及S期作为T1期淋巴结阴性乳腺癌的预后因素

Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer.

作者信息

Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K, Nordling S

机构信息

Fourth Department of Surgery, Helsinki University Central Hospital, Finland.

出版信息

Acta Oncol. 1997;36(4):369-74. doi: 10.3109/02841869709001282.

DOI:10.3109/02841869709001282

PMID:9247096

Abstract

The prognostic value of Ki-67, p53 and ER immunohistochemical labelling and flow-cytometric S-phase fraction and ploidy was evaluated in 212 pT1N0M0 breast carcinomas. The mean follow-up time was 8.3 years. Patients with breast carcinomas with high Ki-67 expression (> or = 10%) had a less favourable disease-free survival than those with low Ki-67 expression (< 10%) (p = 0.008). A positive p53 staining and high SPF were associated with a less favourable disease-free survival although it did not reach statistical significance. The subset of patients with ER negative, Ki-67 > or = 10% and p53 > or = 20% tumours, had a shorter disease-free survival compared with that of all the other patients (p = 0.03). We conclude that the potential value of Ki-67 labelling for prognostic evaluation of T1N0M0 breast carcinoma is good.

摘要

对212例pT1N0M0期乳腺癌患者评估了Ki-67、p53和雌激素受体（ER）免疫组化标记以及流式细胞术检测的S期细胞分数和倍体的预后价值。平均随访时间为8.3年。Ki-67高表达（≥10%）的乳腺癌患者无病生存期不如Ki-67低表达（<10%）的患者（p = 0.008）。p53染色阳性和高S期细胞分数与较差的无病生存期相关，尽管未达到统计学显著性。ER阴性、Ki-67≥10%且p53≥20%肿瘤的患者亚组，与所有其他患者相比无病生存期更短（p = 0.03）。我们得出结论，Ki-67标记对T1N0M0期乳腺癌预后评估的潜在价值良好。